The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! The stock decreased 3.09% or $2.16 during the last trading session, hitting $67.78. About 857,140 shares traded hands or 66.90% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 15.72% since February 29, 2016 and is uptrending. It has outperformed by 5.30% the S&P500.
The move comes after 9 months negative chart setup for the $5.30 billion company. It was reported on Oct, 1 by Barchart.com. We have $62.36 PT which if reached, will make NASDAQ:ALNY worth $424.00 million less.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 9 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Alnylam Pharmaceuticals has been the topic of 19 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. The stock has “Overweight” rating given by Morgan Stanley on Tuesday, August 2. The stock has “Outperform” rating given by Leerink Swann on Tuesday, February 16. The rating was initiated by Jefferies with “Buy” on Friday, October 23. On Tuesday, May 3 the stock rating was maintained by Leerink Swann with “Outperform”. FBR Capital initiated it with “Outperform” rating and $180 target price in Tuesday, August 11 report. On Friday, August 28 the stock rating was maintained by JMP Securities with “Outperform”. The rating was maintained by JP Morgan with “Overweight” on Friday, August 5. The rating was maintained by Piper Jaffray on Monday, August 31 with “Overweight”. TheStreet downgraded the stock to “Hold” rating in Saturday, August 22 report.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio dropped, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
The New York-based Rtw Investments Ltd Liability Corporation has invested 15.78% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Tocqueville Asset Limited Partnership last reported 113,970 shares in the company. Price T Rowe Associate Md owns 4.00M shares or 0.05% of their US portfolio. Moreover, Natixis Asset Mgmt has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,698 shares. Tiaa Cref Inv Mngmt holds 192,417 shares or 0.01% of its portfolio. Blackrock Japan Co Ltd owns 89,754 shares or 0.02% of their US portfolio. Geode Capital Management Llc has 0.02% invested in the company for 499,616 shares. Rockefeller Fincl Services last reported 5,302 shares in the company. New York State Common Retirement Fund, a New York-based fund reported 229,977 shares. Citigroup has 0% invested in the company for 80,876 shares. Morgan Stanley reported 875,104 shares or 0.02% of all its holdings. California Pub Employees Retirement Systems has invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Amp Cap Investors Limited holds 0.01% or 19,559 shares in its portfolio. Sectoral Asset holds 0.06% or 10,000 shares in its portfolio. Amalgamated Bank holds 0.05% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 11,565 shares.
Insider Transactions: Since April 19, 2016, the stock had 0 insider buys, and 2 sales for $3.98 million net activity. $2.03M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares were sold by MARAGANORE JOHN.
More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.” on September 24, 2016, also Fool.com with their article: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals” published on September 02, 2016, Finance.Yahoo.com published: “Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating …” on September 21, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Fool.com and their article: “Alnylam Pharmaceuticals, Inc. Cranks Out the Data” published on August 12, 2016 as well as Fool.com‘s news article titled: “Why Alnylam Pharmaceuticals, Inc. Jumped 10.7% on Friday” with publication date: July 01, 2016.
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.